Application value of liver/spleen CT value， controlled attenuation parameter， and magnetic resonance imaging-proton density fat fraction in chronic hepatitis B patients with hepatic steatosis

Jingnan LU; Yansong LI; Ya WEN; Xionghui WANG; Zhaoyu QU; Jianlong LI; Wei ZHANG

doi:10.12449/JCH240109

Volume 40 Issue 1

Jan. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(1): 46-51

PDF( 1052 KB)

Application value of liver/spleen CT value， controlled attenuation parameter， and magnetic resonance imaging-proton density fat fraction in chronic hepatitis B patients with hepatic steatosis

DOI: 10.12449/JCH240109

1.
Department of Medical Imaging，Affiliated Hospital of Yan’an University，Yan’an，Shaanxi 716000，China
2.
Department of Nuclear Medicine，Xi’an International Medical Center Hospital，Xi’an 710100，China

Research funding:

Science and Technology Research and Development Project of Yan’an (2018KS-11)

More Information

Corresponding author: ZHANG Wei， 304180598@qq.com （ORCID： 0009-0009-2951-1115）
Received Date: 2023-04-20
Accepted Date: 2023-05-06
Published Date: 2024-01-23

Abstract

Abstract

Objective To investigate the application value of liver/spleen CT value （CT_L/S）， controlled attenuation parameter （CAP）， and magnetic resonance imaging-proton density fat fraction （MRI-PDFF） in chronic hepatitis B （CHB） patients with hepatic steatosis. Methods A retrospective analysis was performed for the clinical data of 213 CHB patients who underwent liver CT， CAP， and MRI-PDFF examinations in Affiliated Hospital of Yan’an University from October 2018 to December 2022. According to MRI-PDFF， the 213 patients were divided into CHB group with 111 patients （MRI-PDFF<5%） and CHB+hepatic steatosis group with 102 patients （MRI-PDFF≥5%）， among whom there were 69 patients with mild hepatic steatosis and 33 patients with moderate to severe hepatic steatosis. The independent-samples t test was used for comparison of normally distributed continuous data between groups， and the Mann-Whitney U test was used for comparison of non-normally distributed continuous data between groups. The Bland-Altman plot was used to evaluate the consistency in MRI-PDFF measurement between two physicians. The Spearman’s correlation coefficient was used to analyze the correlation between CT_L/S and MRI-PDFF and between CAP and MRI-PDFF. The receiver operating characteristic （ROC） curve was plotted and the area under the ROC curve （AUC） was calculated to investigate the value of CT_L/S and CAP in the diagnosis of different degrees of hepatic steatosis， and the DeLong test was used to compare the AUCs of the two radiological examinations. Results MRI-PDFF had relatively high repeatability and stability in CHB patients. There is a significant negative correlation between CT_L/S and MRI-PDFF （r=-0.800， P<0.001） and a significant positive correlation between CAP and MRI-PDFF （r=0.692， P<0.001）. Both CT_L/S and CAP had a relatively high accuracy in the diagnosis of hepatic steatosis in CHB patients， with an AUC of 0.951 and 0.902， respectively， and CT_L/S had a better accuracy than CAP （P<0.05）. In the diagnosis of mild and moderate-to-severe hepatic steatosis， CT_L/S had an AUC of 0.921 and 0.895， respectively， and CAP had an AUC of 0.859 and 0.825， respectively， suggesting that CT_L/S had a slightly higher diagnostic efficiency than CAP. Conclusion MRI-PDFF has high repeatability and stability in CHB patients， and CT_L/S and CAP have a high diagnostic value for different degrees of hepatic steatosis in CHB patients.
- Hepatitis B， Chronic,
- Fatty Liver,
- Diagnosis

FullText(HTML)

References(21)

References

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3( 6): 383- 403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	ZHOU WW, HUANG J, PAN FM. Research progress in epidemiological characteristics and therapeutic drugs of chronic hepatitis B[J]. J Changchun Univ Chin Med, 2022, 38( 12): 1420- 1424. DOI: 10.13463/j.cnki.cczyy.2022.12.028. 周薇薇, 黄俊, 潘发明. 慢性乙型肝炎流行病学特点和治疗药物研究进展[J]. 长春中医药大学学报, 2022, 38( 12): 1420- 1424. DOI: 10.13463/j.cnki.cczyy.2022.12.028.
[3]	RINELLA ME, NEUSCHWANDER-TETRI BA, SIDDIQUI MS, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease[J]. Hepatology, 2023, 77( 5): 1797- 1835. DOI: 10.1097/HEP.0000000000000323.
[4]	LEE YB, HA Y, CHON YE, et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B[J]. Clin Mol Hepatol, 2019, 25( 1): 52- 64. DOI: 10.3350/cmh.2018.0040.
[5]	SHIHA G, IBRAHIM A, HELMY A, et al. Asian-Pacific Association for the Study of the Liver(APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update[J]. Hepatol Int, 2017, 11( 1): 1- 30. DOI: 10.1007/s12072-016-9760-3.
[6]	ROGIER J, ROULLET S, CORNÉLIS F, et al. Noninvasive assessment of macrovesicular liver steatosis in cadaveric donors based on computed tomography liver-to-spleen attenuation ratio[J]. Liver Transpl, 2015, 21( 5): 690- 695. DOI: 10.1002/lt.24105.
[7]	FERRAIOLI G. Quantitative assessment of liver steatosis using ultrasound controlled attenuation parameter(Echosens)[J]. J Med Ultrason(2001), 2021, 48( 4): 489- 495. DOI: 10.1007/s10396-021-01106-1.
[8]	Committee of Hepatology, Chinese Research Hospital Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association, National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, et al. Expert recommendations on standardized diagnosis and treatment for fatty liver disease(2019 revised edition)[J]. J Clin Hepatol, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007. 中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会, 中华医学会肝病学分会脂肪肝与酒精性肝病学组, 等. 脂肪性肝病诊疗规范化的专家建议(2019年修订版)[J]. 临床肝胆病杂志, 2019, 35( 11): 2426- 2430. DOI: 10.3969/j.issn.1001-5256.2019.11.007.
[9]	TAMAKI N, AJMERA V, LOOMBA R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD[J]. Nat Rev Endocrinol, 2022, 18( 1): 55- 66. DOI: 10.1038/s41574-021-00584-0.
[10]	DULAI PS, SIRLIN CB, LOOMBA R. MRI and MRE for non-invasive quantitative assessment of hepatic steatosis and fibrosis in NAFLD and NASH: Clinical trials to clinical practice[J]. J Hepatol, 2016, 65( 5): 1006- 1016. DOI: 10.1016/j.jhep.2016.06.005.
[11]	National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007. 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
[12]	YE J, WU Y, LI F, et al. Effect of orlistat on liver fat content in patients with nonalcoholic fatty liver disease with obesity: assessment using magnetic resonance imaging-derived proton density fat fraction[J]. Therap Adv Gastroenterol, 2019, 12: 1756284819879047. DOI: 10.1177/1756284819879047.
[13]	YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in Asia[J]. Liver Int, 2022, 42( 9): 1981- 1990. DOI: 10.1111/liv.15252.
[14]	CASTERA L, FRIEDRICH-RUST M, LOOMBA R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2019, 156( 5): 1264- 1281.e4. DOI: 10.1053/j.gastro.2018.12.036.
[15]	PARK CC, NGUYEN P, HERNANDEZ C, et al. Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease[J]. Gastroenterology, 2017, 152( 3): 598- 607.e2. DOI: 10.1053/j.gastro.2016.10.026.
[16]	LEE SS, PARK SH. Radiologic evaluation of nonalcoholic fatty liver disease[J]. World J Gastroenterol, 2014, 20( 23): 7392- 7402. DOI: 10.3748/wjg.v20.i23.7392.
[17]	ZHONG L, CHEN JJ, CHEN J, et al. Nonalcoholic fatty liver disease: quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy[J]. J Dig Dis, 2009, 10( 4): 315- 320. DOI: 10.1111/j.1751-2980.2009.00402.x.
[18]	CHEN S, HUANG ZH. Advances in quantitative imaging evaluation of non-alcoholic fatty liver disease[J]. J New Clin Medicine, 2018, 11( 12): 1283- 1286. DOI: 10.3969/j.issn.1674-3806.2018.12.32. 陈松, 黄泽和. 非酒精性脂肪肝病的影像学定量评估研究进展[J]. 中国临床新医学, 2018, 11( 12): 1283- 1286. DOI: 10.3969/j.issn.1674-3806.2018.12.32.
[19]	KARLAS T, PETROFF D, SASSO M, et al. Individual patient data meta-analysis of controlled attenuation parameter(CAP) technology for assessing steatosis[J]. J Hepatol, 2017, 66( 5): 1022- 1030. DOI: 10.1016/j.jhep.2016.12.022.
[20]	NOGAMI A, YONEDA M, IWAKI M, et al. Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future[J]. Clin Mol Hepatol, 2023, 29( Suppl): S123- S135. DOI: 10.3350/cmh.2022.0357.
[21]	MA YN, LIU JC. Research progress in the noninvasive quantitative diagnosis of hepatic steatosis using controlled attenuation parameters[J]. Chin J Gastroenterol Hepatol, 2020, 29( 11): 1309- 1312. DOI: 10.3969/j.issn.1006-5709.2020.11.023. 马亚楠, 刘近春. 受控衰减参数无创定量诊断肝脂肪变性的研究进展[J]. 胃肠病学和肝病学杂志, 2020, 29( 11): 1309- 1312. DOI: 10.3969/j.issn.1006-5709.2020.11.023.

Relative Articles

[1]	Gongqin QIU, Dan XIE, Ziren CHEN, Shi OUYANG. Significance of high-sensitivity polymerase chain reaction in detecting hepatitis B virus in chronic hepatitis B patients with a very low viral load[J]. Journal of Clinical Hepatology, 2024, 40(3): 483-488. doi: 10.12449/JCH240308
[2]	Chen YANG, Shanghai YU, Feipeng XU, Hua ZHANG. Application of magnetic resonance imaging-proton density fat fraction in liver fat quantification[J]. Journal of Clinical Hepatology, 2024, 40(3): 600-605. doi: 10.12449/JCH240327
[3]	Xinyu DU, Jia LI, Bei JIANG, Kunyu ZHAO, Yue HU, Fengmei WANG, Fengmin LU. Noninvasive diagnostic indicators for histologically defined immune tolerance state in patients with chronic HBV infection and establishment and assessment of related models[J]. Journal of Clinical Hepatology, 2024, 40(12): 2392-2398. doi: 10.12449/JCH241208
[4]	Ke YIN, Yuyun SONG, Feng LIU. Research advances in chronic hepatitis B with metabolic dysfunction-associated steatotic liver disease[J]. Journal of Clinical Hepatology, 2024, 40(12): 2499-2504. doi: 10.12449/JCH241221
[5]	Hui ZHUANG. Progress towards elimination of hepatitis B[J]. Journal of Clinical Hepatology, 2024, 40(5): 857-860. doi: 10.12449/JCH240501
[6]	Qingrong TANG, Changxiang LAI, Fang WANG, Jin LU, Chunhua XU, Xiangjun LI, Yizhou XU. Establishment of a noninvasive diagnostic model for chronic hepatitis B liver fibrosis patients with normal aminotransferases aged ≤30 years[J]. Journal of Clinical Hepatology, 2024, 40(9): 1790-1795. doi: 10.12449/JCH240912
[7]	Xiaobin LI, Bowen LIU, Feng LI, Xiaopeng SU, Shiping HU. Theory and practice of immunoregulatory therapy with traditional Chinese medicine for chronic hepatitis B[J]. Journal of Clinical Hepatology, 2023, 39(12): 2908-2913. doi: 10.3969/j.issn.1001-5256.2023.12.023
[8]	Baisheng HUANG, Lanxin OU, Yingjie ZHANG, Meijie SHI, Sheng LI, Huanming XIAO, Xiaoling CHI. Value of traditional noninvasive fibrosis models in diagnosis of significant liver fibrosis in patients with chronic hepatitis B and metabolic associated fatty liver disease[J]. Journal of Clinical Hepatology, 2023, 39(9): 2110-2116. doi: 10.3969/j.issn.1001-5256.2023.09.012
[9]	National Workshop on Fatty Liver and Alcoholic Liver Disease，Chinese Society of Hepatology，Chinese Medical Association, Fatty Liver Expert Committee，Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. Journal of Clinical Hepatology, 2018, 34(5): 947-957. doi: 10.3969/j.issn.1001-5256.2018.05.007
[10]	Wan Yan, Chang JianBo, Bai YanXia, Li QianNan, Dai GuangRong. Significance of serological markers in diagnosis of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2017, 33(5): 963-968. doi: 10.3969/j.issn.1001-5256.2017.05.037
[11]	Li Jing, Qi LingLi, Wu Jie. Research advances in the diagnosis of nonalcoholic fatty liver disease in children[J]. Journal of Clinical Hepatology, 2017, 33(10): 2025-2029. doi: 10.3969/j.issn.1001-5256.2017.10.038
[12]	Fan JianGao. Research advances in non- alcoholic fatty liver disease: a review of current status and prospect[J]. Journal of Clinical Hepatology, 2015, 31(7): 999-1001. doi: 10.3969/j.issn.1001-5256.2015.07.001
[13]	Lu JiaFa, Fan JianGao. Research progress in controlled attenuation parameter for assessment of fatty liver disease[J]. Journal of Clinical Hepatology, 2015, 31(5): 806-809. doi: 10.3969/j.issn.1001-5256.2015.05.044
[14]	Liu KeHui, Xie JingDong, Ruan Juan, Yu MinJie, Lin LanYi, An BaoYan, Zhou HuiJuan, Xie Qing, Wang Hui. Value of FibroScan in assessment of liver fibrosis in chronic hepatitis B patients with hepatocyte steatosis[J]. Journal of Clinical Hepatology, 2014, 30(2): 153-157. doi: 10.3969/j.issn.1001-5256.2014.02.014
[15]	Expert Committee on the Diagnosis and Management of Fatty Liver Disease, Chinese Medical Association. Recommendation for the standardization of diagnosis and treatment of fatty liver disease[J]. Journal of Clinical Hepatology, 2013, 29(9): 652-655. doi: 10.3969/j.issn.1001-5256.2013.09.005
[16]	Chen Fei, Yao YaNing, Ma SuMei, Feng Fei, Zou Quan, Xue LiLi. Diagnostic value of acoustic radiation force impulse in patients with non- alcoholic simple fatty liver[J]. Journal of Clinical Hepatology, 2013, 29(10): 756-759. doi: 10.3969/j.issn.1001-5256.2013.10.009
[17]	Ding Sheng, Wang Li, Yan XinMin, Zhou JianYong. Comparison of the diagnosis between CT and B mode ultrasoud in faffy liver.[J]. Journal of Clinical Hepatology, 2002, 18(6): 372-373.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	陈彦孜，唐湘雍，尹安雨，李建华，于大飞，张玉忠. 腹部定量CT和血清脂肪因子与非酒精性脂肪肝相关性分析. 长春中医药大学学报. 2025(02): 199-203 .
2.	杨晨，余上海，徐飞鹏，张华. 磁共振质子密度脂肪分数（MRI-PDFF）在肝脂肪定量中的应用. 临床肝胆病杂志. 2024(03): 600-605 . 本站查看

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Figures(5) / Tables(2)

Get Citation

PDF

XML

Article Metrics

Article views (741) PDF downloads(72)